Synthesis of a red-shifted fluorescence polarization probe for Hsp90

Bioorganic and Medicinal Chemistry Letters

Volumn 16, Issue 17, 2006, Pages 4515-4518

  Moulick, Kamalika ^a   Clement, Cristina C ^a   Aguirre, Julia ^a   Kim, Joungnam ^a   Kang, Yanlong ^a   Felts, Sara ^b   Chiosis, Gabriela ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b MAYO GRADUATE SCHOOL   (United States)

Author keywords

Fluorescence polarization; Hsp90; Red shifted dye

Indexed keywords

FLUORESCENT DYE; FLUORESCENT DYE CY3B GELDANAMYCIN; HEAT SHOCK PROTEIN 90; UNCLASSIFIED DRUG;

ARTICLE; FLUORESCENCE POLARIZATION; SYNTHESIS;

BENZOQUINONES; CARBOCYANINES; COLOR; FLUORESCENCE POLARIZATION; FLUORESCENT DYES; HSP90 HEAT-SHOCK PROTEINS; LACTAMS, MACROCYCLIC; LIGANDS; MOLECULAR STRUCTURE; RIFABUTIN;

EID: 33746222909     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2006.06.025     Document Type: Article

References (23)

1. Neckers L., and Neckers K. Expert Opin. Emerg. Drugs 1 (2005) 137
2. Whitesell L., and Lindquist S.L. Nat. Rev. Cancer 10 (2005) 761
3. Chiosis G. Expert Opin. Ther. Targets 10 (2006) 37
4. Prodromou C., and Pearl L.H. Curr. Cancer Drug Targets 5 (2003) 301
5. Wegele H., Muller L., and Buchner J. Rev. Physiol. Biochem. Pharmacol. 151 (2004) 1
6. Neckers L., Schulte T.W., and Mimnaugh E. Invest. New Drugs 17 (1999) 361
7. Lakowitz J.R. Fluorescence anisotrophy. In: Lakowitz J.R. (Ed). Principles of Fluorescence Spectroscopy. 2nd ed. (1999), Plenum, New York 291-319
8. Kim J., Felts S., Llauger L., He H., Huezo H., Rosen N., and Chiosis G. J. Biomol. Screen. 9 (2004) 375
9. Llauger L., He H., Kim J., Aguirre J., Rosen N., Peters U., Davies P., and Chiosis G. J. Med. Chem. 48 (2005) 2892
10. He H., Zatorska D., Kim J., Aguirre J., Llauger L., She Y., Wu N., Immormino R.M., Gewirth D.T., and Chiosis G. J. Med. Chem. 49 (2006) 381
11. Turek-Etienne T.C., Small E.C., Soh S.C., Xin T.A., Gaitonde P.V., Barrabee E.B., Hart R.F., and Bryant R.W. J. Biomol. Screen. 8 (2003) 176
12. http://www.gehealthcare.com/
13. 2-MeOH (2% TEA)) 0.4. This intermediate (1.2 mg, 0.002 mmol) was added to the cy3B-NHS ester (GE Healthcare#25190114) (1 mg, 0.002 mmol) in dry DMF (50 μL) containing a catalytic amount of DMAP. The resulted mixture was stirred for 1.5 h and applied for purification to an HPLC system. The product was obtained as a pinkish-purple solid (1 mg, 72% yield). MS m/z 1181.3 (M+Na).
14. Clevenger R.C., Raibel J.M., Peck A.M., and Blagg B.S. J. Org. Chem. 69 (2004) 4375
15. Kuduk S.D., Zheng F.F., Sepp-Lorenzino L., Rosen N., and Danishefsky S.J. Bioorg. Med. Chem. Lett. 9 (1999) 1233
16. Chiosis G., Rosen N., and Sepp-Lorenzino L. Bioorg. Med. Chem. Lett. 11 (2001) 909
17. Llauger L., Felts S., Huezo H., Rosen N., and Chiosis G. Bioorg. Med. Chem. Lett. 13 (2003) 3975
18. S. For cy3B-labeled GM, measurements were made with excitation at 530 nm (25-nm bandwidth) and emission at 580 nm (10-nm bandwidth) using a 565 nm dichroic filter. Data were imported into SoftMaxPro4 and analyzed in GraphPad Prizm4.
19. Schulte T.W., and Neckers L.M. Cancer Chemother. Pharmacol. 42 (1998) 273
20. Chiosis G., Lucas B., Shtil A., Huezo H., and Rosen N. Bioorg. Med. Chem. 1 (2002) 3555
21. Vilenchik M., Solit D., Basso M., Huezo H., Lucas B., Huazhong H., Rosen N., Spampinato C., Modrich P., and Chiosis G. Chem. Biol. 11 (2004) 787
22. Carreras C.W., Schirmer A., Zhong Z., and Santi D.V. Anal. Biochem. 317 (2003) 40
23. Chiosis, G. Curr. Topics Med. Chem. 2006, in press.